Castle Biosciences, Inc. (CSTL)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
$34.20-4.34%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
QuarterlyIQ Insights · CSTL
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The Company now anticipates generating between $385-395 million in total revenue in 2026, compared to the previously provided guidance of between $365-375 million.
Stated in 3 of 3 supplied quarters. Management reported: “Document Exhibit 99.1 Castle Biosciences Reports Third Quarter 2026 Results Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025 TissueCypher ® test report volume increased 47% over Q3 2025 Raising full-year 2026 revenue guidance to $385-395 million from $365-375 million Conference call and webcast today at 4:30 p.m.” “The Company now anticipates generating between $385-395 million in total revenue in 2026, compared to the previously provided guidance of between $365-375 million.” Revenue was $102.891 million in 2026-Q3.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company now anticipates generating between $385-395 million in total revenue in 2026, compared to the previously provided guidance of between $365-375 million.”
““Given this momentum, we are raising our 2026 total revenue guidance to $365-375 million, up from our previous range of $345-355 million.”
“As a result of our first quarter performance and continued confidence in the business, we are raising our 2026 total revenue guidance to $345-355 million, compared to the previously provided guidance…”
Further, the Company maintains its expectation to achieve positive Adjusted EBITDA for the fourth quarter 2026, the full year 2026 and the full year 2027.
Stated in 2 of 3 supplied quarters. Management reported: “• Adjusted EBITDA was $12.7 million, compared to $9.2 million for the same period in 2025.” “Further, the Company maintains its expectation to achieve positive Adjusted EBITDA for the fourth quarter 2026, the full year 2026 and the full year 2027.”
“Further, the Company maintains its expectation to achieve positive Adjusted EBITDA for the fourth quarter 2026, the full year 2026 and the full year 2027.”
“We also now expect to achieve positive Adjusted EBITDA for the third quarter, the fourth quarter and the full year 2026.”
“TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.
Stated in 3 of 3 supplied quarters. Management reported: “◦ TissueCypher Barrett’s Esophagus test reports delivered in the quarter were 15,574, compared to 10,609 in the third quarter of 2025.” ““TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.”
““TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.”
“Document Exhibit 99.1 Castle Biosciences Reports Second Quarter 2026 Results Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanom…”
“Document Exhibit 99.1 Castle Biosciences Reports First Quarter 2026 Results Delivered Q1 2026 revenue of $83.7 million Q1 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma,…”
Third Quarter 2026 Highlights Dermatology - Skin Cancer • In September, the Company presented new data on DecisionDx-Melanoma from the largest, prospective multi-center study of gene expression profi…
Stated in 3 of 3 supplied quarters. Management reported: “Third Quarter 2026 Highlights Dermatology - Skin Cancer • In September, the Company presented new data on DecisionDx-Melanoma from the largest, prospective multi-center study of gene expression profiling (GEP) in cutaneous melanoma to date, involving 2,799 patients across 29 U.S. centers.” “Gastroenterology • The Company announced the publication of a study showing that its TissueCypher Barrett’s Esophagus test helped guide risk-aligned management decisions for patients with non-dysplastic Barrett’s esophagus (NDBE).”
“Third Quarter 2026 Highlights Dermatology - Skin Cancer • In September, the Company presented new data on DecisionDx-Melanoma from the largest, prospective multi-center study of gene expression profi…”
“Dermatology - Atopic Dermatitis • The Company announced that its AdvanceAD-Tx test has received assay approval from the New York State Department of Health (NYSDOH).”
““ In addition, during the quarter we expanded the body of evidence supporting our market-leading DecisionDx-Melanoma test.”
Raise full-year 2026 total revenue guidance reflecting strong growth in core test volumes and overall business momentum.
Over the trailing year it converted 0.36x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
Not enough signal yet.
Not investment advice. As of 2026-11-05.